Tag Archives: adalimumab

September, 2018

June, 2017

March, 2017

January, 2017

November, 2016

  • 30 November

    Momenta’s Humira Biosimilar Succeeds in Late-Stage Psoriasis Study

    CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA® (adalimumab) candidate developed in collaboration with Baxalta, now part of Shire plc, in patients with moderate-to-severe chronic plaque psoriasis, met its primary endpoint. The proportion …

September, 2016

July, 2016

June, 2016

  • 15 June

    FDA Panel Scheduled to Review Amgen’s Humira Biosimilar

    THOUSAND OAKS, Calif., June 13, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the Company’s Biologics License Application (BLA) for ABP 501, a biosimilar candidate to Humira® (adalimumab). “With our heritage in both rheumatology …

March, 2016